CellResearch Corporation has been awarded an Innovation Passport for CorLiCyte™

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has been awarded an Innovation Passport for CorLiCyte™, by the UK’s regulatory agencies (MHRA, NICE, SMC), becoming one of only around 20 companies to receive the designation so far.

Adalvo announces successful DCP submission for Lisdexamfetamine Oral Solution

Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data.

Adalvo announces successful DCP closure for Icatibant

Adalvo is pleased to announce the successful closure on our DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to our partners.

Adalvo announces successful DCP filing for Teriflunomide

Adalvo is pleased to announce the successful DCP filing on its Teriflunomide development, a new addition to our high-value product portfolio offering to our partners.

Adalvo announces successful Pivotal BE outcome of Lisdexamfetamine Oral Solution 10mg / ml

Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine Oral Solution 10mg / mlwhich has been developed in close collaboration with Laboserve & Pharma-Data.

Adalvo announces completion of Phase III patient enrollment for Dimethyl Fumarate 30 mg / 120 mg

Adalvo is pleased to announce that we have completed our patient enrollment of our Phase 3 clinical study, to assess the safety and efficacy of Dimethyl Fumarate 30 mg / 120 mg hard capsules, which is being developed in collaboration with one of our strategic partners.

Adalvo and Hansoh Pharma enter into an exclusive license partnership

Adalvo and Jiangsu Hansoh Pharma, a leading R&D-driven pharmaceutical company in China, are pleased to announce that they have entered into an strategic partnership for the commercialization of Fulvestrant pre-filled injection in all EU markets and select Asia-Pacific markets.

Lotus Enhanced Oncology Pipeline

Adalvo is the only B2B platform with a real selected boutique approach to portfolio. We are proud to offer products from all the major pharmaceutical domains, oncology being one of them.

Adalvo submits dossier application for Enzalutamide Soft Gel Capsule 40mg

Adalvo is pleased to announce that following the successful compilation of all necessary requirements, we have submitted our dossier for Enzalutamide, and did proceed for filing via several DCP procedures in Europe.

Adalvo submits generic dossier application for Dimethyl Fumarate hard capsules

Adalvo is pleased to announce that in light of the most recent General Court decision that revoked data exclusivity protection on Dimethyl Fumarate (Tecfidera®) hard capsules, we have submitted our generic dossier application in a DCP procedure.

Teduglutide - A Unique Opportunity With Vast Orphan Market Potential

Adalvo is very excited about this unique opportunity with vast orphan market potential

Adalvo & JSC Olainfarm to launch a new urology product in 17 countries in 2022-2023

Adalvo is delighted to partner with JSC Olainfarm to launch a new product within the urology segment which is targeted to be the 1st to market opportunity in 17 countries. The prescription product will help millions of patients to regain ease and quality of life

Adalvo announces successful pivotal BE trial outcome of Lisdexamfetamine development

Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine hard capsules development which demonstrates Adalvo´s ability to continuously offer first-to-market opportunities to its valued partners.

Adalvo announces DCP filing of Solifenacin+Tamsulosin MR tablets

Adalvo is happy to announce that following the successful compilation of all necessary requirements today we submitted our Solifenacin+Tamsulosin MR Tablet dossier and will proceed via several DCP procedures in Europe

We are pleased to share our exciting DCP schedule for 2021

Here at Adalvo we are committed to being always on target with the aim of achieving great results for our partners and patients.

Adalvo announces ready-to-file dossier completion on Pomalidomide hard capsules development

Adalvo is delighted to announce the completion of an eCTD format dossier on our Pomalidomide hard capsules development.

Adalvo announces successful Pivotal BE trial on Teriflunomide development

Adalvo is happy to claim positive pivotal PK result on its Teriflunomide development which will soon be a new addition to our high-value product portfolio to our customers.

Adalvo announces successful pivotal BE trial outcome of Drospirenone + Estradiol program

We are happy to announce a positive pivotal PK outcome of our Drospirenone + Estradiol development which is our new milestone in creating Adalvo’s mission for a boutique portfolio containing complex and niche products. Adalvo is the only known developer of this asset which underpins our differentiated portfolio strategy

Are you feeling the holiday buzz?

As the Holidays are rapidly approaching, we really wanted to take this opportunity to thank you all for your wonderful collaboration and support in what has undoubtedly been a truly outstanding and remarkable year for all us on pretty much every front.

Adalvo wins Business Development of the Year award at the annual Global Generics Awards

The Adalvo team have certainly been busy bees this year, driven by their passion for relentless commitment to customers and business partners. Adalvo has been a true success story ever since Alvogen and Alvotech introduced the new B2B corporate identity early this year.